Yoshihiro Hattori
-
- Lung Cancer Research Studies 10
- Colorectal Cancer Treatments and Studies 8
- Cancer Immunotherapy and Biomarkers 6
-
- Lung Cancer Treatments and Mutations 22
- Lung Cancer Diagnosis and Treatment 10
- Gastric Cancer Management and Outcomes 2
-
- Chronic Lymphocytic Leukemia Research 2
-
- PI3K/AKT/mTOR signaling in cancer 2
- Co-authors
- Yoshiko UrataShunichi NegoroMiyako SatouchiSoichiro YokotaToshiaki TakahashiHideo SakaAkito HataMotoko Tachihara
- Partner nations
- JapanUnited StatesItaly
In The Last Decade
Yoshihiro Hattori
25 papers receiving 295 citations
Peers
Comparison fields: 5 of 49
- Oncology 215
- Pulmonary and Respiratory Medicine 188
- Cancer Research 23
- Otorhinolaryngology 6
- Immunology 18
Countries citing papers authored by Yoshihiro Hattori
This map shows the geographic impact of Yoshihiro Hattori's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Yoshihiro Hattori with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Yoshihiro Hattori more than expected).
Fields of papers citing papers by Yoshihiro Hattori
This network shows the impact of papers produced by Yoshihiro Hattori. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Yoshihiro Hattori. The network helps show where Yoshihiro Hattori may publish in the future.
Co-authorship network
The 25 scholars most cited alongside Yoshihiro Hattori, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2025 | 0 | |
| 2 | 2023 | 1 | |
| 3 | 2023 | 0 | |
| 4 | 2022 | 1 | |
| 5 | 2021 | 40 | |
| 6 | 2021 | 17 | |
| 7 | 2021 | 3 | |
| 8 | 2020 | 4 | |
| 9 | 2020 | 7 | |
| 10 | Safety/Tolerability of 1L Pembrolizumab+Chemotherapy in Japanese Patients with Metastatic Nonsquamous NSCLC: KEYNOTE-189 | 2019 | 0 |
| 11 | 2019 | 1 | |
| 12 | 2018 | 32 | |
| 13 | 2017 | 4 | |
| 14 | 2016 | 3 | |
| 15 | 2015 | 65 | |
| 16 | 2014 | 16 | |
| 17 | 2013 | 2 | |
| 18 | 2013 | 9 | |
| 19 | [Two cases of advanced pancreatic cancer responding to gemcitabine with long survival of 2 years]. | 2004 | 4 |
| 20 | 1967 | 7 |
About Yoshihiro Hattori
Yoshihiro Hattori is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Genetics, having authored 28 papers that have together received 298 indexed citations. Recurring topics across this work include Lung Cancer Treatments and Mutations (22 papers), Lung Cancer Diagnosis and Treatment (10 papers), Lung Cancer Research Studies (10 papers), Colorectal Cancer Treatments and Studies (8 papers), Cancer Immunotherapy and Biomarkers (6 papers), Chronic Lymphocytic Leukemia Research (2 papers), Gastric Cancer Management and Outcomes (2 papers) and PI3K/AKT/mTOR signaling in cancer (2 papers). The work is most often cited by research in Oncology (215 citations), Pulmonary and Respiratory Medicine (188 citations) and Cancer Research (23 citations). Yoshihiro Hattori has collaborated with scholars based in Japan, United States and Italy. Frequent co-authors include Yoshiko Urata, Shunichi Negoro, Miyako Satouchi, Soichiro Yokota, Toshiaki Takahashi, Hideo Saka, Akito Hata, Motoko Tachihara, Nobuyuki Katakami and Takashi Nishimura.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.